Laurie Reeves
Medical · San Diego, CANPI 1942510698
Payments from drug & device makers
Across 389 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$771
- UCB, Inc.$612
- Otsuka America Pharmaceutical, Inc.$461
- Sanofi-aventis U.S. LLC$417
- Novo Nordisk$412
- Johnson & Johnson$399
- plus $5K from 48 others
What the payments were for
- Food & beverage$7,799100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,813 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $105,324 |
| OzempicSemaglutide | 35 | $42,090 |
| FarxigaDapagliflozin Propanediol | 61 | $29,244 |
| TrulicityDulaglutide | 25 | $27,367 |
| CreonLipase/Protease/Amylase | 12 | $20,986 |
| AptiomEslicarbazepine Acetate | 14 | $18,485 |
| MounjaroTirzepatide | 17 | $15,387 |
| EliquisApixaban | 33 | $13,514 |
| GemtesaVibegron | 17 | $13,226 |
| LinzessLinaclotide | 20 | $11,458 |
| XareltoRivaroxaban | 11 | $10,667 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,021 |
| KerendiaFinerenone | 21 | $6,944 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $4,792 |
| Methenamine Hippurate | 47 | $3,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $55 | $105,32421 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $283 | $43,37454 claims |
| Novo NordiskOzempic | $412 | $42,09035 claims |
| AbbVieCreon, Linzess | $771 | $32,44532 claims |
| AstraZenecaFarxiga, Symbicort | $146 | $31,45273 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $27 | $18,48514 claims |
| PfizerEliquis | $169 | $13,51433 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $49 | $13,22617 claims |
| Johnson & JohnsonXarelto | $399 | $10,66711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $145 | $7,02115 claims |
| BayerKerendia | $94 | $6,94421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.
Other medical in San Diego
- Cheryl KyinnSan Diego$103K
- Touraj YariSan Diego$27K
- Aaron WillcottSan Diego$23K
- Yuchao JinSan Diego$22K
- Carter CopelandSan Diego$17K
- Cameron ChanSan Diego$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.